EVALUATION OF THE EFFECTIVENESS AND SAFETY OF TWO DOSING REGIMENS OF OLOKIZUMAB (OKZ), COMPARED TO PLACEBO, IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) WHO ARE TAKING AN EXISTING MEDICATION CALLED A TUMOUR NECROSIS FACTOR ALPHA INHIBITOR BUT HAVE ACTIVE DISEASE: